Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received a bull case valuation of A$0.35 and a base case valuation of A$0.25 from Pitt Street Research in a report. The analysts highlight that the key catalysts for realising this potential shareholder value are the advancement of the company’s clinical-stage assets through the clinic with the end goal of bringing these assets to market.

Immuron receives bull case valuation of A$0.35 from Pitt Street Research

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) --  (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer,

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical ...

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron signs up second cohort for clinical trial assessing Travelan® in the prevention of travellers' diarrhoea

Second cohort of 34 healthy volunteers enrolled in the Travelan ® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan ® more suited to the US military has commenced the second ...

Immuron Limited: Immuron Announces Travelan Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the

The first cohort in-patient stage of the study was completed in August 2023. Immuron received confirmation that a second cohort of 34 study participants were admitted to the Pharmaron inpatient ...

Immuron Announces Travelan® Clinical Study Cohort 2 Commences

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (IMCIMRN, an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of ...

Get the most recent info and news about Immuron on HackerNoon, where 10k+ technologists publish stories for 4M+ monthly readers.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

IMMURON

immuron.com

-- employees

Since n.d.

COMPANY RANKING

IMMURON

EVERGREEN INDEX #5876

Representing this company? Click here to claim and customize this page!

Immuron WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!

IMMURON

immuron.com

-- employees

Since n.d.

COMPANY RANKING

IMMURON

EVERGREEN INDEX #5876

RELATED COMPANIESRANK

STORIES ABOUT IMMURON

Representing this company? Click here to claim and customize this page!

Immuron WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!